We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Avid Bioservices Inc | NASDAQ:CDMO | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 8.76 | 8.10 | 9.25 | 0 | 12:00:11 |
From May 2019 to May 2024
Abstract: 3059 Title: Phosphatidylserine targeting antibody in combination with anti-PD-1 antibody treatment activates infiltrating T lymphocytes of the spleen and tumor microenvironment in pre-clinical models of melanoma and breast cancer Presenter: Xianming Huang, Ph.D., The University of Texas Southwestern Medical Center Session: Developmental Therapeutics—Immunotherapy Track(s): Developmental Therapeutics and Translational Research Session Type: General Poster Session Time and Location: Saturday, May 30 8:00 AM - 11:30 AM CDT, S Hall A
Abstract: 3060 Title: Activation of CD8+ tumor infiltrating lymphocytes by bavituximab in a 3D ex vivo system of lung cancer patients Presenter: Soner Altiok, M.D, Ph.D., H. Lee Moffitt Cancer Center & Research Institute Session: Developmental Therapeutics—Immunotherapy Track(s): Developmental Therapeutics and Translational Research Session Type: General Poster Session Time and Location: Saturday, May 30 8:00 AM - 11:30 AM CDT, S Hall A
Abstract: 4109 Title: A phase I/II study of bavituximab and sorafenib in advanced hepatocellular carcinoma (HCC) Presenter: Adam Charles Yopp, M.D., The University of Texas Southwestern Medical Center Session: Gastrointestinal (Noncolorectal) Cancer Track(s): Gastrointestinal (Noncolorectal) Cancer Session Type: General Poster Session Time and Location: Monday, Jun 1 8:00 AM - 11:30 AM CDT, S Hall A
In addition, Peregrine will be hosting ASCO conference attendees at booth #22107.
About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a pipeline of novel drug candidates in clinical trials for the treatment and diagnosis of cancer. The company's lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of second-line non-small lung cancer (the "SUNRISE trial") along with several investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. The company is also advancing a molecular imaging agent, 124I-PGN650, in an exploratory clinical trial for the imaging of multiple solid tumor types. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. For more information, please visit www.peregrineinc.com.
Hot Features
Premium
CONTACT: Christopher Keenan
Peregrine Pharmaceuticals, Inc.
(800) 987-8256
info@peregrineinc.com
1 Year Avid Bioservices Chart |
1 Month Avid Bioservices Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
